Background And Purpose: Vascular death rates and hospitalizations for stroke are increased during influenza epidemics. Influenza vaccination may prevent stroke. We investigated whether influenza vaccination is associated independently with reduced odds of stroke and whether effects are confined to stroke subgroups and winter seasons and shared by other vaccinations.
Methods: During 18 months, we performed standardized interviews assessing vaccination status, risk factors, health-related behavior, and socioeconomic factors in 370 consecutive patients with ischemic or hemorrhagic stroke or transient ischemic attack (TIA) and 370 age- and sex-matched control subjects selected randomly from the population.
Results: Influenza vaccination during the last vaccination campaign was less common in patients (19.2%) than control subjects (31.4%; P<0.0001). After adjustment for vascular risk factors, education, health-related behavior and other factors, influenza vaccination (odds ratio [OR], 0.46; 95% CI, 0.28 to 0.77) but not other combined recent vaccinations (OR, 0.80; 95% CI, 0.42 to 1.43) were associated with reduced odds of stroke/TIA. Significant effects were found in men, older subjects (>65 years), subjects with previous vascular diseases, and regarding ischemic stroke; nonsignificant trends existed in women, younger subjects, and regarding hemorrhagic stroke. In etiologic subgroups of cerebral ischemia, similar effects were found. No protective effects were found during summer months; however, results also varied considerably between both winter seasons examined.
Conclusions: These results support the hypothesis that influenza vaccination may be associated with reduced stroke risk. However, residual confounding cannot be excluded, and interventional studies are required to evaluate the role of influenza vaccination in stroke prevention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/01.STR.0000170674.45136.80 | DOI Listing |
ACS Nano
January 2025
Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Multiple sclerosis (MS) is a severe autoimmune disorder that wreaks havoc on the central nervous system, leading to a spectrum of motor and cognitive impairments. There is no cure, and current treatment strategies rely on broad immunosuppression, leaving patients vulnerable to infections. To address this problem, our approach aims to induce antigen-specific tolerance, a much-needed shift in MS therapy.
View Article and Find Full Text PDFHealth Secur
January 2025
Robert A. Johnson, PhD, is Director, Medical Countermeasures Programs, and Gary L. Disbrow, PhD, is Director, Center for Biomedical Advanced Research and Development Authority (BARDA), Washington, DC. Terence M. Barnhart, PhD, is Senior Strategy Implementation Leader, Tunnell Government Services, Inc. (Contractor Supporting BARDA), Washington, DC.
From influenza to COVID-19, emerging infectious diseases have taken a heavy toll on lives and resources. Emerging infectious diseases represent one of the largest threats to national security. The primary mission of the Center for Biomedical Advanced Research and Development Authority (BARDA), within the US Administration for Strategic Preparedness and Response, is to support the advanced development of medical countermeasures (MCMs) for public health security threats, including select infectious diseases.
View Article and Find Full Text PDFJ Med Virol
January 2025
Department of Laboratory Medicine, Ziekenhuis aan de Stroom, Antwerp, Belgium.
Three hospitals implemented molecular point-of-care tests (POCTs) to screen patients for SARS-CoV-2 infection upon admission during the 2021/2022 influenza season, which in Belgium lasted from January to April 2022. The samples were simultaneously tested for influenza A/B. Influenza positivity at admission was examined in relation to patient characteristics and symptomatology.
View Article and Find Full Text PDFObjectives: We assessed the transmission of SARS-CoV-2 and vaccine receipt in a representative sample of wet market workers in a highly dense, low-income setting. Wet markets are key in many Asian settings, including Dhaka, Bangladesh, for fresh food, including animal protein.
Methods: During early 2022, we assessed the prevalence of anti-SARS-CoV-2 antibodies in a random sample of poultry and vegetable workers in 15 wet markets, and investigated associations with socio-demographic characteristics and COVID-19 vaccination.
Nat Commun
January 2025
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
The ongoing circulation of influenza A H5N1 in the United States has raised concerns of a pandemic caused by highly pathogenic avian influenza. Although the United States has stockpiled and is prepared to produce millions of vaccine doses to address an H5N1 pandemic, currently circulating H5N1 viruses contain multiple mutations within the immunodominant head domain of hemagglutinin (HA) compared to the antigens used in stockpiled vaccines. It is unclear if these stockpiled vaccines will need to be updated to match the contemporary H5N1 strains.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!